• Skip to main content
  • Skip to footer

Accuronix

Developing novel cancer therapies

  • Home
  • Founders
  • Approach
  • Contact

January 26, 2016

BioGenerator Leads Investment in Accuronix Therapeutics

Company developing pharmaceuticals to treat the most difficult cancers

BioGenerator, an evergreen investor that creates, grows and invests in promising companies and entrepreneurs, has led a $625,000 investment round in Accuronix Therapeutics, a biotech company developing breakthrough treatments for the most difficult types of cancer.

Accuronix was established based on technologies developed at Washington University in St. Louis by Dr. William Hawkins, Professor of Surgery, and his collaborator, Dr. Robert Mach, Professor of Radiology at University of Pennsylvania. With a particular focus in pancreatic cancer, the company’s mission is to develop novel oncology therapies founded on technology that selectively targets overexpressed receptors on cancer cells.

Read More

Filed Under: News

Footer

About Us

We are applying a novel drug-targeting technology to some of the most difficult problems in cancer therapy.

News & Publications
Financial Conflicts of Interest (FCOI)

Mission

With an initial focus in pancreatic cancer, the Company’s mission is to develop novel oncology therapies based on technology that selectively targets σ-2 receptors overexpressed on cancer cells

Partners

Washington University | University of Pennsylvania | BioGenerator

Contact Us

Accuronix Therapeutics
4340 Duncan Ave.
Suite 210
St. Louis, MO 63110

Contact
Bradley T. Keller, Ph.D.
President and CEO
bkeller@accuronix.com

Copyright © 2023 Accuronix.com · Powered by NeuConcept